Tag Archives: fda

Update: California Delays UTL and Issues New Proposed Rules

After legal challenges from the Premium Cigar Association (PCA) and the Cigar Rights Of America (CRA) in state and federal courts addressing the California Unflavored Tobacco List regulatory scheme, the Attorney General of California has started a process to make several changes.

The Attorney General issued a new proposed rule, seeking comments by Tuesday, December 23rd at 5:00 PM PST. The rule release proposes several changes:

Continue reading Update: California Delays UTL and Issues New Proposed Rules

PCA, CRA, and Manufacturers File Emergency Court Motion to Halt California’s Unworkable Tobacco Regulations

[Washington, D.C. – October 8, 2025] — The Premium Cigar Association (PCA), along with Cigar Rights of America (CRA), Rocky Patel Premium Cigars, Inc., Oliva Cigar Co., Piloto Cigars, Inc. (d/b/a Padrón Cigars, Inc.), A. Fuente & Co., LLC, Ashton Distributors, Inc., Premium Imports, Inc. (d/b/a La Flor Dominicana), and My Father Cigars, has filed an emergency Temporary Restraining Order (TRO) seeking immediate relief from California’s Unflavored Tobacco List (UTL) regulations.

Continue reading PCA, CRA, and Manufacturers File Emergency Court Motion to Halt California’s Unworkable Tobacco Regulations

Cigar Rights of America’s (CRA) Response to Surgeon General’s Report on Tobacco-Related Health Disparities

WASHINGTON, DC (November 19, 2024) – Today, the Office of the Surgeon General released a comprehensive report highlighting the persistent disparities in tobacco use and its health impacts across different population groups. While the report acknowledges significant national progress in reducing smoking rates and secondhand smoke exposure, it emphasizes that these gains have not been equally distributed, with disparities persisting along the lines of race, income, education, geography, and other factors.

Continue reading Cigar Rights of America’s (CRA) Response to Surgeon General’s Report on Tobacco-Related Health Disparities

Congressman Garbarino and Congressman Armstrong Join the Fight to Protect Premium Cigars

Cigar Rights of America (CRA) applauds Congressman Andrew Garbarino (R-NY) and Congressman Kelly Armstrong (R-ND) for officially signing on as co-sponsors of HJ Res. 99, a vital resolution aimed at permanently exempting premium cigars from burdensome FDA regulation.

Continue reading Congressman Garbarino and Congressman Armstrong Join the Fight to Protect Premium Cigars

FDA Center for Tobacco Products Director Dr. Brian King Testifies Before U.S. House Subcommittee on FDA Human Foods and Tobacco Programs

Today, Dr. Brian King, Director of the U.S. Food & Drug Administration’s (FDA) Center for Tobacco Products (CTP), testified before the U.S. House Energy & Commerce Health Subcommittee during a hearing titled, “Evaluating FDA Human Foods and Tobacco Programs.” He was joined by Jim Jones, Deputy Commissioner for Human Foods, to address a range of concerns surrounding tobacco regulations.

Continue reading FDA Center for Tobacco Products Director Dr. Brian King Testifies Before U.S. House Subcommittee on FDA Human Foods and Tobacco Programs

Supreme Court Overrules Chevron Deference

Earlier today (6/28/24), the Supreme Court published their decision in Loper Bright v. Raimondo, a case which significantly curtails the power of federal agencies such as the Food and Drug Administration (FDA) to interpret ambiguous statutes.  The court’s 6-3 ruling struck down a principle known as ‘Chevron Deference,’ a precedent created by the Court in the 1984 case, Chevron v. NRDCChevron essentially allowed Agencies wide latitude in interpreting the scope of their own authority in cases where laws passed by Congress were ambiguous, by requiring judges to strongly defer to the agency’s interpretations of vague statutory language.

Continue reading Supreme Court Overrules Chevron Deference

CRA’s Files Reply Brief In U.S. Court of Appeals

WASHINGTON, DC (April 16, 2024) – Yesterday, Cigar Rights of America (CRA) and the Premium Cigar Association (PCA), filed the industry’s reply brief in response to the United States Food & Drug Administration’s (FDA) appeal in Cigar Association of America, Cigar Rights of America, and Premium Cigar Association v FDA. 

Continue reading CRA’s Files Reply Brief In U.S. Court of Appeals

UNC Research Pushes For Less Freedom on the Golf Course

New “research” from the University of North Carolina (UNC)is proving that even one of America’s last great pastimes, golf, is not safe from the nanny-state agenda. In a research letter published in Nicotine & Tobacco Research, analysts Selena Kleber, Remi Philips, and corresponding author Adam Goldstein, MD, MPH, Director of Tobacco Intervention Programs at the University of North Carolina School of Medicine, examined reports of tobacco sales, sponsorships, and policies at professional golf tournaments. The immediate red flag as to the objectivity of the “research” is the reference to cigarettes in virtually every sentence with cigars.

Continue reading UNC Research Pushes For Less Freedom on the Golf Course

Cigar Rights of America Engages in Critical Dialogue with FDA’s Center for Tobacco Products

WASHINGTON, DC (March 07, 2024) – Today, Cigar Rights of America (CRA) met with Dr. Brian King, Director of the U.S. Food & Drug Administration’s (FDA) Center for Tobacco Products (CTP), to discuss key issues concerning the premium cigar industry, including CTP’s five-year strategic plan and pending proposed regulation to limit nicotine in tobacco products.

Continue reading Cigar Rights of America Engages in Critical Dialogue with FDA’s Center for Tobacco Products

PCA Statement on FDA Appeal of Premium Cigar Ruling

On January 31, 2024, the U.S. Food and Drug Administration (FDA) filed its appealing Judge Amit Mehta’s orders holding the FDA’s decision to regulate premium cigars arbitrary and capricious and vacating it. The appeal is presented to the court of appeals in Washington, D.C., known as the United States Court of Appeals for the D.C. Circuit.

Continue reading PCA Statement on FDA Appeal of Premium Cigar Ruling

ADMINISTRATION REGULATION AND THANKS REPRESENTATIVE STEVEN HORSFORD FOR SERVING AS THE LEAD DEMOCRATIC CO-SPONSOR

(Note: Image of Congressional sponsors would not upload)

Cigar Rights of America (CRA) has been at the vanguard of the fight against the Food & Drug Administration’s (FDA) efforts to regulate premium cigars under the Family Smoking Prevention and Tobacco Control Act (TCA) of 2009. Those efforts came to a head with the issuance of the FDA’s Deeming Rule in 2016, which brought cigars specifically under the FDA’s regulatory jurisdiction.

Continue reading ADMINISTRATION REGULATION AND THANKS REPRESENTATIVE STEVEN HORSFORD FOR SERVING AS THE LEAD DEMOCRATIC CO-SPONSOR

Judges: FDA acted improperly, EPA exceeded authority

A district court ruled the FDA did not properly adhere to the requirements of the Administrative Procedures Act by ignoring the evidence supporting a premium cigar exemption from regulation.

This comes on the heels of the U.S. Supreme Court ruling last Thursday stating Congress did not give the Environmental Protection Agency authority to make broad requirements of states in the climate fight.

“Agencies have only those powers given to them by Congress,” Chief Justice John Roberts wrote. “The agency … must point to ‘clear congressional authorization’ for the power it claims.”

The ruling yesterday called the FDA’s move “arbitrary and capricious.” The judge gave the opportunity for both sides to submit additional briefings before he issues his final judgement after July 26.

Credit has to be given to Premium Cigar Association, the Cigar Rights of America and the Cigar Association of America, Inc. for years of research, lobbying and lawsuits.

“Please understand this is and has been an incredibly complex and difficult task to get our Government’s Regulatory Bureaucracy to respond,” cigar manufacturer Steve Saka posted on Facebook. “A tremendous effort has been expended legislatively and legally to get us to this point.

“Without their efforts, I am not even sure if Dunbarton Tobacco & Trust would be in business today,” he added.

In June, the FDA ordered the vaping company Juul to pull its devices and nicotine liquid pods off shelves, determining they had not shown enough evidence that its products do not hurt public health.

“On July 5, 2022, FDA administratively stayed the marketing denial order” the FDA said in a twitter post. “The agency has determined that there are scientific issues unique to the JUUL application that warrant additional review.”

The stay temporarily suspended the marketing denial order during the additional review but did not rescind it. The message added the stay “does not constitute authorization to market, sell, or ship JUUL products.”